PDGFRB and Mobius syndrome: Based on previous reports that c-MYC over-expression is critical for MB progression [10, 13], we reasoned that co-targeting both PDGFRβ and c-MYC could maximize the suppression of MB progression, especially in SHH and Group 3 MBs.